Toltrazuril

Tocilizumab is a humanized monoclonal antibody used primarily in veterinary medicine, especially in large animals and pets, as an immunomodulator. It is able to inhibit the activity of interleukin-6 (IL-6) and has therapeutic effects on certain immune-mediated diseases.

Melting point: 194-196°C

Density: 1.54±0.1 g/cm3 (Predicted)

Storage conditions: Sealed in dry, Room Temperature

1. Pharmacological action

Tocilizumab inhibits IL-6 signal transduction by binding to the IL-6 receptor, thereby reducing inflammatory and immune responses.

Suitable for the treatment of inflammatory and autoimmune diseases mediated by IL-6.

2. Indications

Rheumatoid arthritis: used to treat animals with rheumatoid arthritis to relieve pain and inflammation.

Acute respiratory distress syndrome: can be used as an adjuvant treatment for severe cases to improve the respiratory condition of animals.

Other immune-mediated diseases: such as skin diseases, inflammatory bowel disease, etc., to help control symptoms.

3. Administration

Toltrazuril is usually administered intravenously or subcutaneously. The specific dose and frequency of administration should be adjusted according to the advice of the veterinarian.

The dose should be determined according to the weight of the animal and the severity of the disease.

4. Precautions

Allergic reactions: Some animals may be allergic to Toltrazuril. The health status of the animal should be confirmed before use.

Risk of infection: Due to the immunosuppressive effect, animals using Toltrazuril may increase the risk of infection and need to be closely observed.

Pregnancy and lactation: Be cautious when using it in pregnant and lactating animals and follow the guidance of a veterinarian.